• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy Research and Practice >New Agents Targeting Angiogenesis in Glioblastoma
【24h】

New Agents Targeting Angiogenesis in Glioblastoma

机译：针对胶质母细胞瘤血管生成的新药物

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Glioblastoma is the most common malignant glioma in adults, and despite recent advances in standard treatment, the prognosis still remains dismal, with a median survival of 15 months. The incorporation of bevacizumab in the standard treatment of relapsed glioblastoma has been a significant step towards combining targeted agents with chemotherapy, and there is an increasing number of new antiangiogenic agents in various stages of development, that are being tested both in relapsed and newly diagnosed disease, alone or in combination with standard treatment. The relatively favorable toxicity profile for most of them presents an advantage, but several concerns arise regarding their actual efficacy on the clinical level and the most efficient schedule of administration for each of them, as their molecular targets and patterns of action may vary significantly. This may lead to future modifications of the current rational of administering these agents concomitantly with initial chemotherapy or maintenance treatment.
机译：胶质母细胞瘤是成人中最常见的恶性神经胶质瘤，尽管最近标准治疗取得了进展，但预后仍然令人沮丧，中位生存期为15个月。贝伐单抗在复发性胶质母细胞瘤的标准治疗中的合并是将靶向药物与化学疗法相结合的重要一步，并且在发展的各个阶段，越来越多的新抗血管生成药物正在复发和新诊断的疾病中进行测试，单独使用或与标准治疗组合使用。对于它们大多数而言，相对有利的毒性特征具有优势，但是由于它们的分子靶标和作用方式可能有很大不同，因此在其临床水平上的实际疗效以及对每种药物的最有效给药方案方面引起了一些关注。这可能导致将来修改与最初的化学疗法或维持治疗同时使用这些药物的合理性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号